Relapsed/Refractory Multiple Myeloma: Evidence-Based Approaches to Therapy Selection and Sequencing
Journal of the National Comprehensive Cancer Network · 2026-05 · 24 (Supplement) · 34-36
DOI: 10.6004/jnccn.2026.5010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2026-05. Verfasst von Shaji K. Kumar. Die Arbeit nennt 20 Literaturangaben.
Abstract (Originalsprache)
Monitoring and detection of relapse are key components of the current treatment paradigm for relapsed or refractory (R/R) multiple myeloma. The degree of clinical disease and biochemical disease progression, as well as the drug classes patients have been exposed or are refractory to, guides the sequencing and timing of therapies for patients with R/R disease. Supportive care focusing on bone health, infection, and thrombosis remains important for these patients. The cornerstones of management of R/R multiple myeloma are a multidisciplinary approach and early referral to tertiary cancer centers.
Zitieren
APA
Kumar, S. K. (2026). Relapsed/Refractory Multiple Myeloma: Evidence-Based Approaches to Therapy Selection and Sequencing. Journal of the National Comprehensive Cancer Network, 24(Supplement), 34-36. https://doi.org/10.6004/jnccn.2026.5010
Vancouver
Kumar SK. Relapsed/Refractory Multiple Myeloma: Evidence-Based Approaches to Therapy Selection and Sequencing. Journal of the National Comprehensive Cancer Network. 2026;24(Supplement):34-36. doi:10.6004/jnccn.2026.5010
BibTeX
@article{Kumar2026,
author = {Kumar, Shaji K.},
title = {Relapsed/Refractory Multiple Myeloma: Evidence-Based Approaches to Therapy Selection and Sequencing},
journal = {Journal of the National Comprehensive Cancer Network},
year = {2026},
volume = {24},
number = {Supplement},
pages = {34--36},
doi = {10.6004/jnccn.2026.5010}
}
EUVIMED